Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The most commonly used medications to treat OAB have anticholinergic properties. Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor ...

SMPL Hyderabad Telangana [India] January 7 Lux Hospitals Hyderabad proudly announces the launch of the ENDOANAL Real-Time ...

With this tool, a fall-risk score is based on a patient's mental status, cognition, mobility, vision, history of falls, urinary urgency or incontinence, and medications. Patients receive points ...

Francis Medical Inc., a Twin Cities med-tech manufacturer that's developing a way to treat prostrate and other cancers with water vapor, said Tuesday it raised $80 million in its latest equity funding ...

In today’s fast-paced world, many women are turning a blind eye to a common yet often unspoken issue: urinary incontinence.

Habitually getting up to pee in the middle of the night can impact sleep quality. Here's how to cut down on these nighty ...